Relmada Therapeutics (RLMD) Accumulated Expenses (2014 - 2026)
Relmada Therapeutics (RLMD) recorded Accumulated Expenses of $5.01 million in Q2 2026, up 32.8% from $3.77 million a year earlier but down 30.0% from the prior quarter.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Accumulated Expenses (2014 - 2026) Analysis & Trends
At the end of FY2025, Relmada Therapeutics reported Accumulated Expenses of $4.86 million, down 21.1% from FY2024.
- Annual Accumulated Expenses has a five-year compound annual growth rate of 2.7% (FY2020 to FY2025).
- Across earlier years, Accumulated Expenses came in at $6.16 million in FY2024 (-29.1%), $8.69 million in FY2023 (+20.6%), $7.21 million in FY2022 (+86.3%) and $3.87 million in FY2021 (-9.1%).
- Quarterly Accumulated Expenses has ranged from $3.74 million in Q3 2025 to $11.38 million in Q2 2022 over the past five years.
- On a year-over-year basis, Accumulated Expenses rose in three of the last eight quarters, with an average decline of 5.4%.
- Peak year-over-year performance for Accumulated Expenses in the last five years was growth of 228.9% in Q2 2022, against a decline of 48.6% in Q2 2023 at the low end.
- Per Business Quant, the preceding three quarters came in at $7.16 million (Q1 2026), $4.86 million (Q4 2025) and $3.74 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn |
| 10 | Relmada Therapeutics | 402.15 Mn | 402.15 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.01 Mn |
| Mar 31, 2026 | 7.16 Mn |
| Dec 31, 2025 | 4.86 Mn |
| Sep 30, 2025 | 3.74 Mn |
| Jun 30, 2025 | 3.77 Mn |
| Mar 31, 2025 | 3.97 Mn |
| Dec 31, 2024 | 6.16 Mn |
| Sep 30, 2024 | 5.74 Mn |
| Jun 30, 2024 | 5.36 Mn |
| Mar 31, 2024 | 7.17 Mn |
| Dec 31, 2023 | 8.69 Mn |
| Sep 30, 2023 | 5.57 Mn |
| Jun 30, 2023 | 5.85 Mn |
| Mar 31, 2023 | 5.68 Mn |
| Dec 31, 2022 | 7.21 Mn |
| Sep 30, 2022 | 10.35 Mn |
| Jun 30, 2022 | 11.38 Mn |
| Mar 31, 2022 | 4.74 Mn |
| Dec 31, 2021 | 3.87 Mn |
| Sep 30, 2021 | 5.54 Mn |
API Access
Relmada Therapeutics Accumulated Expenses API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=RLMD&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "accumulated-expenses", "ticker": "RLMD", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=RLMD&period=max&api_key=YOUR_API_KEY");
const data = await res.json();